Together, our findings illuminate the role of HDAC1 in TDP‐43 proteinopathies and further support the hypothesis that restoring HDAC1 activity may be a feasible approach to treating FTLD‐TDP and ALS. This evidence concerns the gene HDAC1 and amyotrophic lateral sclerosis.